Yichang Humanwell Pharmaceutical Co., Ltd (hereinafter referred to as Humanwell) was established on August 8th, 2001. Its predecessor, Hubei Yiyao Group, was a long historical standing pharmaceutical conglomerate built in 1954. 

Humanwell is the largest government designated anesthetics developer and manufacturer domestically. Being granted the award as Key Hi-Tech Enterprise of China, Humanwell now owns more than 70 patents, and possesses 26 finished dosage production lines and 7 narcotic  API  production lines which are national top-ranking and Chinese GMP certified. Furthermore, Humanwell is Hubei province’s first pharmaceutical company whose finished dosage and API production lines are certified by US FDA and EU GMP. Humanwell is the first domestic company to successfully develop Fentanyl  Citrate  Injection, National  Second  Category  New  Drug  Remifentanil  Hydrochloride  for  Injection, National Third Category New Drug Sufentanil Citrate Injection, Hydromorphone Hydrochloride Injection, Nalbuphine Hydrochloride Injection and many other industry leading anesthetic APIs and finished dosages. Apart from narcotic and psychotropic drugs, Humanwell also provides many well-known and non-controlled drugs whose brand names are famous to the public. As a prestigious company in the global pharmaceutical industry, Humanwell exports APIs and finished dosages to USA, Europe, Africa and other continents.

Envisioning to the future, Humanwell will embrace the company philosophy of Everyone is Healthy and Happy, take Improve Life Quality, Create Life Happiness as the mission and be led by the core value of Revering Life, Respecting Science, Sharing Results to eventually fulfill the vision of To Become Leader in Anesthesia Field, To Create World-leading Enterprise, as well as contributing to the health undertaking of humanity! 

Yichang Humanwell Oral Solid Dosage Plant (OSD) is a global pharmaceutical company which uses technology and innovation to meet the everyday needs of all patients. OSD is located in the center of China in Yichang City, designed by CRB (US Engineering firm) and construction supervision by MWG Life Sciences (Germany Engineering firm) to comply with USFDA, CFDA, and EMA regulatory requirements. Today in a tightly regulated environment, OSD manufacturing facilities has been inspected by US FDA with Zero Observation twice in June, 2016 and January, 2017. What’s more, UK MHRA inspected OSD Plant from Feb.26th to Mar.1st 2018, and OSD has successfully received the GMP certificate issued by MHRA on April.26 2018. 

OSD is dedicated to developing, manufacturing and supplying extended generic products and monograph OTC in the regulated markets. It has developed a product line which treats conditions such as depression, hypertension, diabetes, hypokalemia, etc. Its facility has a manufacturing capacity of 4 billion tablets and 1 billion capsules using multiple packaging lines. OSD has maintained a good communication and cooperation for a long time with the international top three pharmaceutical distributors and will become the one of the largest suppliers of Beads Coating Extended Release Products in the world.

Facility:
Our API workshop was inspected by EDQM for fentanyl citrate and obtained EU GMP certificate in the end of 2016. In the same year, this workshop obtained South Korea GMP certificate for Remifentanil Hydrochloride.
Our Small Volume Injection Workshop and Lyophilization & Emulsion work possess INVIMA GMP certificate as well as Uganda GMP certificate for Fentanyl Citrate Injection production line and Remifentanil HCL for Injection production line. 

Our Oral Solid Dosage plant has been approved by US FDA with zero defects.

Registration:
All products of Yichang Humanwell Pharmaceutical have been registered at CFDA and all production lines have obtained ChinaGMP approval. Many products have been registered in countries or areas such as Chile, Sri Lanka, Phillippines, Hong Kong and etc.
CEP certification is available for Fentanyl Citrate, and CEP certification for Remifentanil Hydrochloride will be obtained around the second half of 2018.

Products:
Our products export to Europe, USA, Africa, Central and South America, Australia and other emerging markets. We are also the first domestic company who successfully transferred narcotic drug manufacturing technology to Indonesia.